scholarly journals Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study

2012 ◽  
Vol 160 (2) ◽  
pp. 199-206 ◽  
Author(s):  
Firoozeh Sahebi ◽  
Yan Shen ◽  
Sandra H. Thomas ◽  
Amalia Rincon ◽  
Joyce Murata-Collins ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation ◽  
Follow Up Study ◽  
Long Term Follow Up ◽  
Reduced Intensity

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 1019-1019 ◽  
Author(s):  
Haefaa Alchalby ◽  
Tatjana Zabelina ◽  
Daniel Wolff ◽  
Guido Kobbe ◽  
Martin Bornhäuser ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Allogeneic Transplantation ◽  
Prospective Multicenter Study ◽  
Long Term Follow Up ◽  
Reduced Intensity

Abstract Abstract 1019 Allogeneic stem cell transplantation is the only curative treatment for myelofibrosis. Here we present a long–term follow up of patients with myelofibrosis treated with reduced-intensity allogeneic stem cell transplantation in the prospective multicenter study conducted by the MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (study registration NCT 00599547). From 2002 to 2007, a total of 103 patients with primary (63 pts) or post-polycythemia vera and –essential thrombocythemia myelofibrosis (40 pts) from seventeen transplantation centers in three nations were included in the study. There were 62 males and 41 females with a median age of 55 years (range, 32–68 years). Risk profile according to Lille score was low risk with constitutional symptoms (17%), intermediate risk (53%) and high risk (30%). All but three of the patients received peripheral stem cells as stem cell source from either related (n=33) or unrelated donor (n=70) and a conditioning with Busulfan (10mg/kg orally or 8mg/kg intravenously),Fludarabin (180 mg/m2) and antithymocyte-globulin (ATG-Fresenius®) according a previously published protocol. According to high-resolution HLA typing, 21 patients had at least one allele or antigen HLA mismatch. From 88 patients with a known JAK2V617F-status 63 harbored the mutation. After a median follow up of 60 months (range 9–109 months), 41 patients had chronic graft vs. host disease which was extensive in the half of cases. The 5-year and 8-year estimated overall survival (OS) was 68% and 65%, respectively with a stable plateau after 5,3 years follow up (Figure-1). Estimated 5-year disease-free survival was 40%. The cumulative incidence of relapse/progression at 3 and 5 years was 22% and 28% and the non-relapse mortality at 1 and at 3 years was 18% ands 21%, respectively.Figure-1Figure-1. Within the overall follow up period, relapse/progression occurred in 28 patients. Twenty one of them were treated with donor-lymphocyte infusions (DLI) and/or a second allogeneic transplantation (n=11). Sixteen of those were at the last follow up alive. The estimated OS of all relapsed patients after a median follow up of 46 months (range 4–62 months) beginning from the time of relapse was 55%. In multivariate analysis advanced age >55years (HR: 4.69, p=0.001), absence of JAK2V617F mutation (HR: 2.50, p=0.02), mismatched donor (HR: 3.62, p=0.002) were significant independent predictors for reduced OS. This update of a prospective trial using reduced intensity conditioning followed by allogeneic stem cell transplantation for myelofibrosis confirmed a very good long-term OS. Relapse still occurs in about 30% and remains the main problem after transplantation. However, with adoptive immunotherapy using DLI or even second allogeneic transplantation a second remission with long term survival can be induced in about 50% of the relapsed patients. Developing methods for remission monitoring and early prediction and treatment of relapse should be the focus of future studies. Disclosures: Kobbe: Celgene: Consultancy, Research Funding; Ortho Biotec: Consultancy. de Witte:Novartis: Consultancy, Honoraria, Speakers Bureau.

scholarly journals Treatment of Multiple Myeloma and Macroglobulinemia Waldenström: A Long-Term Follow-Up Study

1975 ◽  
Vol 116 (4) ◽  
pp. 317-325 ◽  
Author(s):  
SEIJU ONODERA ◽  
MASAMICHI OHTAKI ◽  
KOSUKE OIKAWA ◽  
MASATSUGU MIKAMI ◽  
ISAO SATO ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Follow Up Study ◽  
Long Term Follow Up

scholarly journals Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?

2020 ◽  
Vol 9 (7) ◽  
pp. 2180
Author(s):  
Gösta Gahrton ◽  
Simona Iacobelli ◽  
Laurent Garderet ◽  
Ibrahim Yakoub-Agha ◽  
Stefan Schönland
Keyword(s):  
Multiple Myeloma ◽  
Proteasome Inhibitors ◽  
Allogeneic Transplantation ◽  
Reduced Intensity Conditioning ◽  
Cell Therapies ◽  
Novel Drugs ◽  
Car T ◽  
Long Term Follow Up

Novel drugs have improved survival for patients with multiple myeloma in recent years. However, the disease is still fatal. Allogeneic stem cell transplantation (Allo) has proven to cure some patients with the disease, but its role is controversial due to relatively high transplant-related toxicity and mortality (nonrelapse mortality, NRM). Using nonmyeloablative reduced-intensity conditioning (RIC), both toxicity and NRM can be reduced, and RICAllo is, therefore, an option for subgroups of patients. Upfront tandem autologous/RICAllo (Auto/RICAllo) was shown to be superior to single Auto or tandem Auto/Auto in both progression-free (PFS) and overall survival (OS) in two prospective studies with long-term follow-up, while three similarly designed studies did not detect a difference. A recent update of pooled patient data from four of these studies showed significantly superior PFS and OS with Auto/RICAllo. Importantly, none of these studies showed inferior results with Auto/RICAllo in patients less than 70 years of age. Auto/RICAllo appears to overcome some poor risk cytogenetic markers. Encouraging results have also been seen in treatment of relapsed patients. Combining Allo with new proteasome inhibitors and immunomodulatory drugs may further improve results. Other encouraging new cell therapies such as with CAR T-cells, NK- and CAR NK-cells may well have a place in combination with RICAllo. Such studies are warranted.

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

Leukemia ◽  
2019 ◽  
Vol 33 (11) ◽  
pp. 2710-2719 ◽  
Author(s):  
Stefan Knop ◽  
◽  
Monika Engelhardt ◽  
Peter Liebisch ◽  
Christoph Meisner ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Subgroup Analysis ◽  
Allogeneic Transplantation ◽  
Long Term Follow Up

Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis

2019 ◽  
Author(s):  
Stefan Knop ◽  
Monika Engelhardt ◽  
Peter Liebisch ◽  
Christoph Meisner ◽  
Ernst Holler ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Subgroup Analysis ◽  
Allogeneic Transplantation ◽  
Long Term Follow Up

Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution

2016 ◽  
Vol 97 (5) ◽  
pp. 479-488 ◽  
Author(s):  
Laurens E. Franssen ◽  
Reinier A. P. Raymakers ◽  
Arjan Buijs ◽  
Marian F. Schmitz ◽  
Suzanne van Dorp ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation ◽  
Newly Diagnosed ◽  
Single Institution ◽  
Refractory Multiple Myeloma ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document